Healthcare Industry News: DCVax
News Release - March 8, 2007
Northwest Biotherapeutics, Inc. Appoints Chief Financial OfficerBOTHELL, Wash., March 8 (HSMN NewsFeed) -- Northwest Biotherapeutics, Inc. (Nasdaq: NWBT ) announced today that Jim Johnston, J.D., has been appointed as the company's Chief Financial Officer (CFO).
Mr. Johnston has served as NWBT's General Counsel on an internal and external basis since 1998, and served as the company's Chief Financial Officer for the period following the Company's initial public offering on NASDAQ. He currently serves as the company's internal General Counsel, heading up the corporate legal department, and will continue in this role in addition to serving as CFO.
Prior to joining NWBT, Mr. Johnston was in private practice with his law firm based in Bellevue, WA, and before that served as a partner in the business and finance practice of Lane Powell LLC. He also practiced as a certified public accountant in Seattle, Washington, for over ten years. Mr. Johnston holds both J.D. and MST degrees.
"Jim will make an outstanding addition to Northwest Biotherapeutics' senior management team," stated Alton Boynton, President of Northwest Biotherapeutics. "We look forward to his contributions as we move forward with our pivotal Phase II clinical trial in brain cancer, and with our pipeline of clinical trials in six other cancers."
About Northwest Biotherapeutics:
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company's three lead product candidates are:
* DCVax®-Brain, a personalized dendritic cell vaccine for treatment of Glioblastoma multiforme, which has entered into a large Phase II pivotal clinical trial cleared by the FDA;
* DCVax®-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is ready to enter a Phase III pivotal clinical trial cleared by the FDA; and
* Monoclonal antibodies to CXCR4, which are in late pre-clinical development for the treatment of multiple cancers.
For further information, please visit the company web site at www.nwbio.com .
The Company also has a robust pipeline of additional products cleared by FDA for early stage clinical trials in five other cancers beyond brain and prostate cancers.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the company's ability to raise additional capital, risks related to the company's ability to enroll patients in its Phase II clinical trial of DCVax®-Brain and complete the trial on a timely basis, the uncertainty of the clinical trials process, the timely performance of third parties, and whether DCVax®-Brain will demonstrate safety and efficacy and the timely performance of third parties. Additional information on these and other factors, which could affect the company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the company's SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
Source: Northwest Biotherapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.